FindTrial
Sign In

HEpatic and CArdiac TOxicity Systems modelling.

HEpatic and CArdiac TOxicity Systems modelling. - HeCaToS.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40984
Enrollment
500
Registered
2014-11-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiotoxic cardiomyopathy heart failure.

Interventions

None listed

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Patients who have received trastuzumab, epirubicin, doxorubicin, mitoxantrone, daunorubicin, rituximab, idarubicin or taxane treatment for breast cancer, leukaemia*s or lymphomas. -Age between 18 and 70 years.

Exclusion criteria

Exclusion criteria: Known cardiac diseases or cardiac abnormalities in the past.

Design outcomes

Primary

MeasureTime frame
Primary endpoint: development of cardiotoxicity, defined as the most recent guidelines: a reduction of LVEF >5% to LVEF 10% to a LVEF—

Secondary

MeasureTime frame
Myocardial injury, hypertension, trombo embolic events (veneous trombo embolism/TIA/CVA), bradycardia and QT prolongation on ECG.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)